Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Cash & Equivalents (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Cash & Equivalents for 16 consecutive years, with $13.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 986.59% to $13.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.3 million, a 986.59% increase, with the full-year FY2024 number at $76000.0, down 99.11% from a year prior.
  • Cash & Equivalents was $13.3 million for Q3 2025 at Plus Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $21.3 million in Q3 2021 to a low of $74000.0 in Q1 2024.
  • A 5-year average of $11.4 million and a median of $11.9 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 99.42% in 2024, then skyrocketed 13233.78% in 2025.
  • Plus Therapeutics' Cash & Equivalents stood at $21.3 million in 2021, then dropped by 14.85% to $18.1 million in 2022, then crashed by 52.79% to $8.6 million in 2023, then tumbled by 99.11% to $76000.0 in 2024, then skyrocketed by 17385.53% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Cash & Equivalents are $13.3 million (Q3 2025), $2.2 million (Q2 2025), and $9.9 million (Q1 2025).